Meta-analysis of rare and adverse event data

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 2, Issue 4, 2002, Pages 367-379

  Sutton, Alexander J ^a   Cooper, Nicola J ^a   Lambert, Paul C ^a   Jones, David R ^a   Abrams, Keith R ^a   Sweeting, Michael J ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Adverse event; Bayesian methods; Breast implants; Cesarean section; Meta analysis; Methodology; Rare events; Side effect; Sparse data; Statistical; Systematic review

Indexed keywords

ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; HEPARIN; PLACEBO; TAXANE DERIVATIVE; WARFARIN;

ANTIBIOTIC PROPHYLAXIS; BAYES THEOREM; BLEEDING; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SURVEILLANCE PROGRAM; ECONOMIC ASPECT; HEART ATRIUM FIBRILLATION; HUMAN; META ANALYSIS; OUTCOMES RESEARCH; RANDOMIZED CONTROLLED TRIAL; REVIEW; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS; STROKE; WOUND INFECTION;

EID: 0036045435     PISSN: 14737167     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737167.2.4.367     Document Type: Review

References (73)

1. Methods for meta-analysis in medical research
2. Evidence-based medicine: What it is and what it isn't
3. Statistical principles for clinical trials
4. The many modes of meta
5. How do Cochrane reviewers address adverse effects of drug therapy?
6. Completeness of safety reporting in randomized trials: An evaluation of 7 medical areas
7. The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomised trials
8. Improving safety reporting from randomised trials
9. Incomplete evidence: The inadequacy of databases in tracing published adverse drug reactions in clinical trials
10. Does research synthesis have a place in drug regulatory policy? Synopsis of issues: Assessment of safety and postmarketing surveillance
11. Postmarketing surveillance and adverse drug reactions: Current perspectives and future needs
12. Food and Drug Administration monitoring of adverse drug reactions
13. Common technical document for the registration of pharmaceuticals for human use
14. Impact of postmenopausal hormone therapy on cardiovascular events and cancer: Pooled data from clinical trials
15. Impact of postmenopausal hormone therapy on cardiovascular events and cancer. More women are excluded from treatment arm of such trials because of cardiovascular events
16. Impact of postmenopausal hormone therapy on cardiovascular events and cancer. Search for studies was limited
17. Impact of postmenopausal hormone therapy on cardiovascular events and cancer. Paper's main conclusion is no longer justifies when data from all trials are considered
18. Impact of postmenopausal hormone therapy on cardiovascular events and cancer. Combining thromboembolic events with cardiovascular events does not support odds ratio of 0.7
19. Impact of postmenopausal hormone therapy on cardiovascular events and cancer. Inclusion of one particular study was inappropriate
20. Impact of postmenopausal hormone therapy on cardiovascular events and cancer. Study's conclusions were incorrect
21. A meta-analysis of breast implants and connective tissue disease
22. Estimating a relative risk across sparse case-control and follow-up studies: A method for meta-analysis
23. Anticoagulant-related bleeding: Clinical epidemiology, prediction and prevention
24. Antibiotic prophylaxis for cesarean section
25. The statistical basis of meta-analysis
26. A general parametric approach to the meta-analysis of randomised clinical trials
27. Meta-analysis in clinical trials
28. Meta-analysis software
29. Much ado about nothing: Statistical methods for meta-analysis with rare events
30. Detecting and describing heterogeneity in meta-analysis
31. What to add to nothing? The use and avoidance of continuity corrections in meta-analysis of rare events
32. Multilevel models for meta-analysis and their application to absolute risk differences
33. Advanced methods in meta-analysis: Multivariate approach and meta-regression
34. A bivariate approach to meta-analysis
35. Methods in health service research: An introduction to Bayesian methods in health technology assessment
36. Markov Chain Monte Carlo in practice
37. Bayesian methods in health technology assessment
38. Bayesian statistics: An introduction
39. Bayesian methods in meta-analysis and evidence synthesis
40. Bayesian approaches to random-effects meta-analysis: A comparative study
41. Bayesian random effects meta-analysis of trials with binary outcomes: Methods for the absolute risk difference and relative risk scales
42. Assessing the quality of randomised controlled trials: Current issues and future directions
43. Assessing the quality of randomized controlled trials - An annotated-bibliography of scales and checklists
44. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of healthcare interventions
45. Combining studies using effect sizes and quality scores: Application to bone loss in postmenopausal women
46. The hazards of scoring the quality of clinical trials for meta-analysis
47. Meta-analysis by the Confidence Profile Method
48. Hierarchical models in generalised synthesis of evidence: An example based on studies of breast cancer screening
49. Random effects models for combining results from controlled and uncontrolled studies in a meta-analysis
50. Publication and other selection biases in systematic reviews
51. Modelling publication bias in meta-analysis: A review
52. What is publication? A continuum
53. Assessing the potential for bias in meta-analysis due to selective reporting of subgroup analyses within studies
54. Bias in meta-analysis due to outcome variable selection within studies
55. An evidence based approach to individualizing treatment
56. A Bayesian approach to evaluating net-clinical benefit
57. Markov models in medical decision making: A practical guide
58. Use of Bayesian methods for markov modelling in cost-effectiveness analysis: An application to taxane use in advanced breast cancer
59. Effect measures for meta-analysis of trials with binary outcomes
60. Metan - An alternative meta-analysis command
61. Weighting bias in meta-analysis of binary outcomes
62. Numbers needed to treat derived from meta-analyses - Sometimes informative, usually misleading
63. An assessment of the use of the continuity correction for sparse data in metaanalysis
64. An introduction to categorical data analysis
65. Combining estimates of the odds ratio: The state of the art
66. Randomized comparison of five irrigation solutions at cesarean section
67. Prophylactic short course rectal metronidazole for cesarean section. A double-blind controlled trial of a simple low cost regimen
68. Antibiotic prophylaxis in low-risk cesarean section
69. Post-cesarean section febrile morbidity
70. Antibiotic prophylactic uterine lavage in cesarean section: A double-blind comparison of saline, ticarcillin, and cefoxitin irrigation in indigent patients
71. A double-blind randomized controlled trial on the use of prophylactic antibiotics in patients undergoing elective caesarean section
72. Prophylactic antibiotics in cesarean section